Corvallis-based Siga Technologies will get a $79 million payment for a smallpox drug it developed as part of U.S. defenses against terror and biological attacks.
Corvallis-based Siga Technologies will get a $79 million payment for a smallpox drug it developed as part of U.S. defenses against terror and biological attacks.
The money, when it arrives, will be the first cash payment for a deliverable product ever received by Siga Technologies, which has been working to bring a drug to market since its founding in 1995.
While it has yet to be approved by the U.S. Food and Drug Administration for general use, the Biomedical Advanced Research and Development Authority has ordered 2 million courses of the drug for a national stockpile.
Read more at The Register-Guard.
